Can Fibromyalgia Kill You? A Look at Life Expectancy

Fibromyalgia does not directly cause death the way a heart attack or cancer does. No one dies “of” fibromyalgia in the way a death certificate would record organ failure or a tumor. But the condition is not neutral when it comes to life expectancy. A 2023 meta-analysis found that people with fibromyalgia had a roughly 27% higher risk of dying from any cause compared to those without it. That modest but real bump in mortality comes not from the pain itself but from a web of complications, comorbidities, and treatment side effects that accumulate over years of living with the condition.

What the Mortality Data Actually Show

The research on whether fibromyalgia shortens life is surprisingly mixed. The largest and most cited study followed over 8,186 patients across 35 years and found no statistically significant increase in mortality. The overall standardized mortality ratio in that cohort was 0.90, and when compared with osteoarthritis patients (a group with a similar chronic-pain burden), fibromyalgia patients had essentially the same death rate.¹ On the surface, that looks reassuring.

But a 2023 systematic review and meta-analysis that pooled multiple studies came to a different conclusion, finding a hazard ratio of 1.27 for all-cause mortality in fibromyalgia patients.² That means, across the pooled data, people with fibromyalgia were about a quarter more likely to die during the study periods than people without it. The discrepancy between these findings comes down partly to how fibromyalgia was diagnosed. The meta-analysis noted that the elevated mortality appeared in studies using broader or more recent diagnostic criteria, while studies relying strictly on the older 1990 classification criteria (which required physical tender-point exams) did not show the same increase. This matters because the diagnostic criteria capture somewhat different patient populations, and the broader net picks up more people with overlapping psychiatric and metabolic conditions.

The honest takeaway is that fibromyalgia probably does shorten life expectancy for some patients, but the effect is modest and driven almost entirely by indirect causes rather than the disease itself. Understanding those indirect causes is what matters most for anyone living with the condition.

Suicide Is the Most Alarming Risk

If there is one mortality-related statistic that people with fibromyalgia need to hear, it is this: the risk of suicide is substantially elevated compared to the general population. One study found that fibromyalgia patients were roughly 10 times more likely to die by suicide.³ A meta-analysis covering over 390,000 fibromyalgia patients found that suicide attempts had a pooled prevalence of about 6%, and that the odds of attempting suicide were roughly three times higher than in the general population.⁴

The drivers behind this are not mysterious. Fibromyalgia involves relentless pain, sleep deprivation, cognitive fog, and in many cases a feeling of not being believed by the medical system. Depression and anxiety co-occur frequently. In one review of over 1,100 medical records, roughly 29% of fibromyalgia patients had a documented diagnosis of depression and/or anxiety.⁵ Among men with fibromyalgia in that same study, the rate climbed to about 43%. Research examining patients with both fibromyalgia and migraine found that about 18% reported having attempted suicide, significantly more than migraine patients without fibromyalgia.⁶ The intersection of chronic pain and psychiatric illness creates a feedback loop where each condition amplifies the other, and the cumulative burden pushes some patients to a breaking point.

This is probably where fibromyalgia’s mortality risk concentrates most heavily, and it is the most preventable piece of the picture. Screening for suicidal ideation in pain clinics, ensuring patients have access to mental health care, and taking depression in fibromyalgia patients seriously as a medical emergency rather than an expected consequence of chronic pain are all actionable steps.

The Heart Disease Connection

Heart disease is the leading cause of death globally, and fibromyalgia appears to increase its likelihood through several interconnected pathways. A population-based cohort study in Taiwan found that, after adjusting for other risk factors, fibromyalgia patients had roughly double the risk of developing a coronary heart disease event compared to matched controls.⁷ A second large Taiwanese study confirmed the association, finding that coronary events occurred at a higher rate in fibromyalgia patients even after accounting for traditional cardiovascular risk factors like hypertension and diabetes, as well as for depression and anxiety.⁸

Part of the explanation involves the autonomic nervous system. In fibromyalgia, the branch of the nervous system that controls heart rate, blood pressure, and digestion does not work normally. Multiple studies have found that fibromyalgia patients show lower heart rate variability, meaning the heart is less flexible in how it responds to changing demands. A systematic review confirmed that fibromyalgia patients tend to have reduced parasympathetic (“rest and digest”) activity and heightened sympathetic (“fight or flight”) activity, even at night when the body should be recovering.⁹ A 2023 clinical trial also found that fibromyalgia patients had higher resting heart rates and that their autonomic stress response was blunted compared to healthy controls.¹⁰ Over years, this chronic sympathetic overdrive wears on the cardiovascular system. Other features common in fibromyalgia, including elevated body mass, physical inactivity, and metabolic changes, compound this further.¹¹

Medication Risks and Polypharmacy

Fibromyalgia has no cure, so treatment tends to involve managing symptoms one at a time. The result is often a tall stack of medications, and those combinations carry their own mortality risks. A pharmacological analysis of fibromyalgia patients’ drug regimens recorded 881 alerts across the patients studied. About 64% of those alerts were classified as requiring immediate action by healthcare professionals, mostly because of risks related to serotonin syndrome, excessive sedation, or depression of the central nervous system. Among patients taking tramadol (an opioid-like pain reliever), roughly 59% were also taking one or more benzodiazepines, a combination that raises the risk of respiratory depression and death.¹²

The risks extend beyond accidental drug interactions. Opioid prescribing for fibromyalgia remains common despite guidelines warning against it, and research has identified factors that predict long-term opioid use in these patients: higher initial doses, a history of self-harm, obesity, socioeconomic deprivation, and substance use disorders.¹³ People who start on high doses are far more likely to stay on them indefinitely. Even among non-opioid medications, the picture is complicated. A study of patients starting duloxetine, one of the three FDA-approved drugs for fibromyalgia, found that about 62% had potential drug-drug interactions at the time of initiation.¹⁴ The antidepressants most commonly used to treat fibromyalgia pain, particularly SNRIs and tricyclics, were responsible for over half of the most significant drug interaction alerts in the pharmacological analysis mentioned above.

The danger here is not that any single medication is lethal when used properly. It is that fibromyalgia patients tend to see multiple specialists who each add something to the regimen, and nobody steps back to evaluate the whole cocktail. A pain specialist prescribes tramadol, a psychiatrist adds an SSRI, a primary care doctor prescribes a benzodiazepine for anxiety, and the combined effect on the central nervous system can become dangerous.

Falls, Deconditioning, and the Slow Spiral

Fibromyalgia increases fall risk. Research has consistently found that people with the condition fall more often than healthy controls, with worse balance scores and higher fall-risk indices.¹⁵ The reasons are straightforward: chronic pain changes how you move, poor sleep degrades coordination and reaction time, and many fibromyalgia medications (especially sedating ones) impair balance. For younger patients, a fall might mean a bruise. For older patients, falls are a leading cause of injury-related death, and fibromyalgia adds to that baseline risk.¹⁶

Falls are part of a larger problem: physical deconditioning. When every movement hurts, people naturally move less. Over months and years, less movement leads to muscle loss, weight gain, and reduced cardiovascular fitness. Fibromyalgia patients commonly have elevated body mass and are physically inactive, both major risk factors for metabolic problems like diabetes and heart disease. This creates a vicious cycle where pain limits activity, inactivity worsens metabolic health, and metabolic decline makes the pain harder to manage. The mortality risk from fibromyalgia is, to a meaningful degree, the accumulated mortality risk of prolonged physical inactivity.

Sleep Apnea and Overlapping Conditions

One of the more underappreciated complications of fibromyalgia is its frequent overlap with obstructive sleep apnea. In one study, half of fibromyalgia patients were found to have sleep apnea when formally tested with overnight sleep monitoring, and of those, 42% had the severe form.¹⁷ Untreated sleep apnea carries its own mortality burden through cardiovascular strain, high blood pressure, and metabolic disruption. In some cases, treating the sleep apnea resolves the fibromyalgia symptoms entirely. A case report documented a fibromyalgia patient whose symptoms vanished after wearing a mandibular advancement device during sleep to treat her obstructive sleep apnea.¹⁸ That is a single case, not a generalizable treatment, but it illustrates how deeply intertwined fibromyalgia is with sleep physiology and how much undetected sleep problems can contribute to the overall disease burden.

Sleep apnea is not the only condition that hides behind or alongside fibromyalgia. An estimated 25% of patients with systemic rheumatological diseases like lupus also meet the diagnostic criteria for fibromyalgia.¹⁹ That overlap creates a real danger of diagnostic masking, where symptoms of a potentially serious autoimmune condition get attributed to fibromyalgia and go untreated. Misdiagnosis and symptom dismissal have been documented as causes of delayed recognition of conditions like lupus, with considerable patient distress as a result.²⁰ This is a less obvious pathway to worse outcomes, but it is a real one: if your doctors think your new symptoms are “just the fibromyalgia,” a treatable disease that could shorten your life might go undetected for years.

What Helps and What the Evidence Says About Exercise

Given that much of fibromyalgia’s mortality risk flows through inactivity, cardiovascular decline, and metabolic problems, exercise is the single most important intervention with evidence behind it. A meta-analysis of 24 randomized controlled trials found that exercise significantly reduced pain and fatigue and improved quality of life in fibromyalgia patients. Aerobic exercise in particular produced the largest pain improvements, especially when done regularly for at least eight weeks.²¹ A Cochrane review reached similar conclusions, finding that aerobic training likely improved health-related quality of life and may reduce pain and stiffness while improving physical and cardiovascular function.²²

Strength training also has strong evidence behind it, with reviews documenting large improvements in overall well-being and physical function.²³ The challenge, of course, is that exercise is exactly what hurts most. The research consistently shows that starting gently and building gradually is more effective than aggressive programs, and that frequency matters less than consistency. Sessions of around 60 to 90 minutes, fewer than three times per week, actually outperformed more frequent or shorter sessions for pain relief in the subgroup analyses. This is one area where more is not necessarily better, and where the goal is sustainable movement rather than athletic performance.

Socioeconomic Factors That Compound the Risk

Fibromyalgia does not exist in a vacuum. A Danish cohort study found that people with fibromyalgia had significantly higher rates of comorbid conditions, more contact with all sectors of the healthcare system, lower incomes, higher unemployment, and a greater likelihood of disability pension than matched controls. Those disadvantages showed up years before diagnosis and persisted afterward. Even the spouses of fibromyalgia patients had worse health and economic outcomes.²⁴

This matters for mortality because poverty and unemployment are themselves risk factors for early death. Financial stress limits access to care, healthy food, and safe exercise environments. It increases reliance on cheaper but riskier medications. It worsens depression. When researchers find a mortality gap in fibromyalgia, it is hard to separate how much comes from the disease’s biology and how much from the socioeconomic spiral it triggers.

Gender Differences in How the Disease Plays Out

Fibromyalgia affects women far more often than men, but the pattern of complications differs by sex. A large study using Veterans Health Administration data found that women with fibromyalgia were younger at diagnosis and more likely to have headaches, connective tissue diseases, and psychiatric conditions, while men had more comorbid medical conditions overall.²⁵ A UK population-based study added that women with fibromyalgia had higher body mass and more gastrointestinal disorders, while men received gabapentin more often and women received more antidepressants, anxiolytics, and steroids.²⁶

These patterns suggest that the mortality risks from fibromyalgia are distributed differently between men and women. Men may face more cardiovascular and metabolic danger, while women may be more exposed to the psychiatric and medication-related risks. But men with fibromyalgia also face the problem of being less likely to be diagnosed in the first place, since the condition is often perceived as a “women’s disease.” Delayed diagnosis in men could mean more time accumulating untreated complications.

The Inflammation Question

For decades, fibromyalgia was considered a condition of central pain processing with no real inflammatory component. That view has shifted. A meta-analysis found that fibromyalgia patients have modestly elevated levels of several inflammatory markers, including TNF-alpha, interleukin-6, and interleukin-8, compared to healthy controls.²⁷ A growing body of evidence supports a role for neuroinflammation and immune changes in fibromyalgia’s mechanisms.²⁸

The elevations are small, nowhere near what you would see in rheumatoid arthritis or lupus. But chronic low-grade inflammation, even at modest levels, is independently linked to cardiovascular disease, metabolic dysfunction, and cognitive decline. If fibromyalgia does involve persistent neuroinflammation, it could help explain why the cardiovascular risks remain elevated even after adjusting for obvious lifestyle factors. This is still an active area of research, and the data are not yet definitive enough to change treatment approaches. But it adds another plausible biological pathway through which the condition could shorten life, beyond the indirect lifestyle effects. The stress-hormone picture is similarly complicated: fibromyalgia patients tend to show signs of adrenal underactivity alongside heightened sympathetic nervous system tone, a pattern that some researchers describe as a mismatch between the brain’s stress alarm system and the body’s ability to mount an appropriate cortisol response.²⁹ Whether this dysfunction contributes to mortality directly is unknown, but it fits with the broader picture of a body locked in a state of chronic physiological stress.